Partho Sen, MS, PhD
AstraZeneca (Sweden), University of Turku, Université Montpellier Faculté des Sciences de Montpellier, National Institute of Pharmaceutical Education and Research Kolkata, Mayo Clinic
Research areas: Biochemistry, Genetics and Molecular Biology · Molecular Biology · Metabolomics and Mass Spectrometry Studies · Gut microbiota and health · Microbial Metabolic Engineering and Bioproduction
0000-0003-0475-2763
About
Over 14 years of experience in computational biology and data science in both academia and industry, my professional journey has been marked to unravel the complexity of biological processes and disease mechanism(s) in humans. By utilization of multi-omics (epi) genomics, transcriptomics, proteomics and metabolomics) datasets and Machine Learning/Artificial Intelligence (AI) approaches, I tend to delineate molecular signatures and pathways associated with Cardiovascular Disease (CVD), contributing to the biomarker discovery. My prior research has delved into various health conditions, including, Cancer and Metabolic diseases; Non-Alcoholic Fatty Liver Disease (NAFLD). The overarching objective of my work is to identify molecular markers that serve as key insights into disease mechanisms and underlying pathways. Thereby, aim to formulate innovative drugs and therapeutic strategies.
In addition to my proficiency in mathematical, statistical modeling and data science, I am an accomplished computer programmer; well-versed in machine learning. My passion lies in harnessing large datasets to design tools that address contemporary challenges in healthcare. I am confident that with my expertise, we can achieve significant breakthroughs in understanding and treating diseases that have hitherto posed significant challenges.
Employment
-
AstraZeneca (Sweden) Principal Scientist2025 - Present
-
Mayo Clinic Data Scientist2023 - 2025
-
University of Turku Adjunct Professor/Docent in Computational Biology2022 - Present
-
Deutsches Herzzentrum München Senior scientist & Bioinformatician2022 - 2023
-
Örebro University Affiliated Researcher2018 - 2022
-
Turku Bioscience Senior Postdoctoral Researcher2017 - 2022
-
Chalmers tekniska högskola - Campus Lindholmen Postdoctoral fellow2014 - 2017
-
Jawaharlal Nehru University School of Computational and Integrative Sciences Junior Research Fellow2009 - 2010
Education
-
Université Montpellier Faculté des Sciences de Montpellier PhD2010 - 2013
-
National Institute of Pharmaceutical Education and Research Kolkata M.S Pharm2007 - 2009
- 2003 - 2007
Projects & Funding
Projects & funding information is unavailable.
Publications (65)
- Dynamics of gut metabolome and microbiota maturation during early life. Save
- An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum. Save
- Dysregulation of microbiota in first episode psychosis patients were associated with symptom severity and treatment response. Save
- Unique 40-year survival after heart transplantation with normal graft function and spontaneous operational tolerance. Save
- Abstract 15391: Five-Year Outcomes in Patients With Acute Coronary Syndrome and Myocardial Revascularization Treated With Prasugrel or Ticagrelor Save
- Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children. Save
- Integrating Omics Data in Genome-Scale Metabolic Modeling: A Methodological Perspective for Precision Medicine Save
- Dynamics of Gut Metabolome and Microbiome Maturation during Early Life Save
- Use of big data from health insurance for assessment of cardiovascular outcomes. Save
- Deep learning facilitates multi-data type analysis and predictive biomarker discovery in cancer precision medicine Save
- Deep learning facilitates multi-data type analysis and predictive biomarker discovery in cancer precision medicine Save
- Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes Save
- Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease. Save
- Quantitative modelling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease Save
- Metabolomic and proteomic profiling in bipolar disorder patients revealed potential molecular signatures related to hemostasis Save
- Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease Save
- Dynamics of gut microbiome – mediated bile acid metabolism in progression to islet autoimmunity Save
- Conjugated C-6 hydroxylated bile acids in serum relate to human metabolic health and gut Clostridia species Save
- 1‐Deoxyceramides – Key players in lipotoxicity and progression to type 2 diabetes? Save
- Deep learning meets metabolomics: a methodological perspective Save